title: [Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma].
abstract: The treatment of choice for patients over 60 years of age with aggressive non-Hodgkin's lymphoma (NHL) consists of chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Because of poor tolerance, dose reductions and delays occur frequently. However, because of the relatively low dose intensity significantly more patients die of refractory or relapse lymphoma. If it is intended to cure these patients, unmitigated CHOP chemotherapy should be applied. When needed additional supportive care can be provided.
authors.affiliation: Academisch Ziekenhuis Rotterdam-Dijkzigt, afd. Hematologie, Rotterdam.
authors.forename: P
authors.initials: P
authors.lastname: Sonneveld
authors.forename: P C
authors.initials: PC
authors.lastname: Huijgens
authors.forename: A
authors.initials: A
authors.lastname: Hagenbeek
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002985:Clinical Protocols / Q000592:standards; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone